News

Calyxt to Host Third Quarter 2022 Financial Results Conference Call and Webcast on Thursday, November 3, 2022, at 4:30 p.m. Eastern Time
October 27, 2022
ROSEVILLE, Minn., Oct. 27, 2022 /PRNewswire/ -- Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, will host a conference call and webcast on...
Read More

Calyxt Successfully Produces Plant-Based Squalene, an Important Ingredient in Personal Care Products and Critical Vaccine Adjuvants
October 25, 2022
ROSEVILLE, Minn., Oct. 25, 2022 /PRNewswire/ -- Calyxt, Inc. (NASDAQ: CLXT), a plant-based synthetic biology company, announced today that using a Calyxt-engineered...
Read More

Calyxt Announces Agreement with Evologic Technologies to Scale Production of its Plant-based Ingredients
October 6, 2022
Agreement will power speed-to-scale strategy to meet the growing interest in high-quality sustainable ingredients across the cosmeceutical, nutraceutical and pharmaceutical...
Read More

Calyxt, Inc. Exploring Strategic Alternatives
September 22, 2022
ROSEVILLE, Minn., Sept. 22, 2022 /PRNewswire/ -- Calyxt, Inc. (NASDAQ: CLXT) ("Calyxt"), a plant-based synthetic biology company, today announced that its Board...
Read More

Calyxt to Present at the H.C. Wainwright 24th Annual Investment Conference
September 7, 2022
ROSEVILLE, Minn., Sept. 7, 2022 /PRNewswire/ -- Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, today announced that Michael A. Carr, President and Chief...
Read More